Renal cell carcinoma metastases to bone after a 33-year remission

Stephen Parada, Jillian M. Franklin, Paul S. Uribe, Mark W. Manoso

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Renal cell carcinoma accounts for 2% of all cancers. Metastases to bone occur 35% to 40% of the time, second in prevalence of metastases only to the lungs. These metastases are highly destructive, hypervascular tumors known to be difficult to manage. This article reports a unique case in which a patient was disease free for 33 years from initial nephrectomy for treatment of primary renal cell carcinoma to discovery of metastatic disease to the pelvis. Search for an unknown primary was performed, consisting of a complete blood count, chemistry, alkaline phosphatase, calcium, serum and urine protein electrophoresis, immunoglobulin levels, prostate specific antigen, liver function tests, bone scan, and chest, abdomen, and pelvis computed tomography scans. This workup was negative for any other primary source of malignancy, and the patient's remaining kidney was found to be free from any tumor burden. The patient successfully underwent excisional biopsy of the lesion, which proved to be vascular in nature, consistent with the final pathology of renal cell carcinoma. The longest amount of time from completion of treatment for the primary renal cell carcinoma to discovery of the first metastatic disease has previously been reported at 22.3 years. Mean interval between primary treatment and discovery of metastases has been defined as 3.0±5.4 years. This article highlights the need for advanced medical workup as well as maintaining a high clinical suspicion in patients with remote histories of primary malignancies who present with bony lesions.

Original languageEnglish (US)
Number of pages1
JournalOrthopedics
Volume32
Issue number6
DOIs
StatePublished - Jun 1 2009
Externally publishedYes

Fingerprint

Renal Cell Carcinoma
Neoplasm Metastasis
Bone and Bones
Pelvis
Neoplasms
Blood Cell Count
Liver Function Tests
Prostate-Specific Antigen
Tumor Burden
Nephrectomy
Abdomen
Alkaline Phosphatase
Blood Vessels
Electrophoresis
Immunoglobulins
Blood Proteins
Thorax
Therapeutics
Tomography
Urine

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine

Cite this

Renal cell carcinoma metastases to bone after a 33-year remission. / Parada, Stephen; Franklin, Jillian M.; Uribe, Paul S.; Manoso, Mark W.

In: Orthopedics, Vol. 32, No. 6, 01.06.2009.

Research output: Contribution to journalArticle

Parada, Stephen ; Franklin, Jillian M. ; Uribe, Paul S. ; Manoso, Mark W. / Renal cell carcinoma metastases to bone after a 33-year remission. In: Orthopedics. 2009 ; Vol. 32, No. 6.
@article{235ce07115ca493aa4bc013d70fd99da,
title = "Renal cell carcinoma metastases to bone after a 33-year remission",
abstract = "Renal cell carcinoma accounts for 2{\%} of all cancers. Metastases to bone occur 35{\%} to 40{\%} of the time, second in prevalence of metastases only to the lungs. These metastases are highly destructive, hypervascular tumors known to be difficult to manage. This article reports a unique case in which a patient was disease free for 33 years from initial nephrectomy for treatment of primary renal cell carcinoma to discovery of metastatic disease to the pelvis. Search for an unknown primary was performed, consisting of a complete blood count, chemistry, alkaline phosphatase, calcium, serum and urine protein electrophoresis, immunoglobulin levels, prostate specific antigen, liver function tests, bone scan, and chest, abdomen, and pelvis computed tomography scans. This workup was negative for any other primary source of malignancy, and the patient's remaining kidney was found to be free from any tumor burden. The patient successfully underwent excisional biopsy of the lesion, which proved to be vascular in nature, consistent with the final pathology of renal cell carcinoma. The longest amount of time from completion of treatment for the primary renal cell carcinoma to discovery of the first metastatic disease has previously been reported at 22.3 years. Mean interval between primary treatment and discovery of metastases has been defined as 3.0±5.4 years. This article highlights the need for advanced medical workup as well as maintaining a high clinical suspicion in patients with remote histories of primary malignancies who present with bony lesions.",
author = "Stephen Parada and Franklin, {Jillian M.} and Uribe, {Paul S.} and Manoso, {Mark W.}",
year = "2009",
month = "6",
day = "1",
doi = "10.3928/01477447-20090511-27",
language = "English (US)",
volume = "32",
journal = "Orthopedics",
issn = "0147-7447",
publisher = "Slack Incorporated",
number = "6",

}

TY - JOUR

T1 - Renal cell carcinoma metastases to bone after a 33-year remission

AU - Parada, Stephen

AU - Franklin, Jillian M.

AU - Uribe, Paul S.

AU - Manoso, Mark W.

PY - 2009/6/1

Y1 - 2009/6/1

N2 - Renal cell carcinoma accounts for 2% of all cancers. Metastases to bone occur 35% to 40% of the time, second in prevalence of metastases only to the lungs. These metastases are highly destructive, hypervascular tumors known to be difficult to manage. This article reports a unique case in which a patient was disease free for 33 years from initial nephrectomy for treatment of primary renal cell carcinoma to discovery of metastatic disease to the pelvis. Search for an unknown primary was performed, consisting of a complete blood count, chemistry, alkaline phosphatase, calcium, serum and urine protein electrophoresis, immunoglobulin levels, prostate specific antigen, liver function tests, bone scan, and chest, abdomen, and pelvis computed tomography scans. This workup was negative for any other primary source of malignancy, and the patient's remaining kidney was found to be free from any tumor burden. The patient successfully underwent excisional biopsy of the lesion, which proved to be vascular in nature, consistent with the final pathology of renal cell carcinoma. The longest amount of time from completion of treatment for the primary renal cell carcinoma to discovery of the first metastatic disease has previously been reported at 22.3 years. Mean interval between primary treatment and discovery of metastases has been defined as 3.0±5.4 years. This article highlights the need for advanced medical workup as well as maintaining a high clinical suspicion in patients with remote histories of primary malignancies who present with bony lesions.

AB - Renal cell carcinoma accounts for 2% of all cancers. Metastases to bone occur 35% to 40% of the time, second in prevalence of metastases only to the lungs. These metastases are highly destructive, hypervascular tumors known to be difficult to manage. This article reports a unique case in which a patient was disease free for 33 years from initial nephrectomy for treatment of primary renal cell carcinoma to discovery of metastatic disease to the pelvis. Search for an unknown primary was performed, consisting of a complete blood count, chemistry, alkaline phosphatase, calcium, serum and urine protein electrophoresis, immunoglobulin levels, prostate specific antigen, liver function tests, bone scan, and chest, abdomen, and pelvis computed tomography scans. This workup was negative for any other primary source of malignancy, and the patient's remaining kidney was found to be free from any tumor burden. The patient successfully underwent excisional biopsy of the lesion, which proved to be vascular in nature, consistent with the final pathology of renal cell carcinoma. The longest amount of time from completion of treatment for the primary renal cell carcinoma to discovery of the first metastatic disease has previously been reported at 22.3 years. Mean interval between primary treatment and discovery of metastases has been defined as 3.0±5.4 years. This article highlights the need for advanced medical workup as well as maintaining a high clinical suspicion in patients with remote histories of primary malignancies who present with bony lesions.

UR - http://www.scopus.com/inward/record.url?scp=70349171771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349171771&partnerID=8YFLogxK

U2 - 10.3928/01477447-20090511-27

DO - 10.3928/01477447-20090511-27

M3 - Article

VL - 32

JO - Orthopedics

JF - Orthopedics

SN - 0147-7447

IS - 6

ER -